SCHEDULE 13G 0000879169 XXXXXXXX LIVE Common Stock, par value $0.0001 per share 11/03/2025 0001678660 Prelude Therapeutics, Inc. 74065P101 175 Innovation Boulevard Wilmington DE 19805 Rule 13d-1(c) INCYTE CORP DE 4372124.00 0.00 4372124.00 0.00 4372124.00 N 9.9 CO See Item 4 below regarding the information set forth in this table. Prelude Therapeutics, Inc. 175 Innovation Boulevard, Wilmington, DE 19805 Incyte Corporation 1801 Augustine Cut-Off, Wilmington, DE 19803 Delaware Y 4,372,124 - See footnote 1 below. (1) The number of shares beneficially owned by Incyte sets forth the number of shares of voting Common Stock that may be currently acquired upon conversion of non-voting Common Stock of Prelude ("Non-Voting Common Stock") convertible on a 1-for-1 basis at any time at the election of Incyte. The shares of Non-Voting Common Stock are only convertible to the extent that, after giving effect to such conversion, Incyte would beneficially own, for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended, no more than 9.99% of the outstanding shares of voting Common Stock (the "Beneficial Ownership Limitation"). By written notice to Prelude, Incyte may from time to time increase or decrease the Beneficial Ownership Limitation applicable to Incyte to any other percentage not in excess of 19.99%. Any such change will not be effective until the 61st day after such notice is delivered to Prelude. As a result of this restriction, the number of shares that may be issued upon conversion of the Non-Voting Common Stock by Incyte may change depending upon changes in the number of outstanding shares of voting Common Stock. 1,877,876 shares of Non-Voting Common Stock held by Incyte are not currently convertible into shares of voting Common Stock due to the effect of the Beneficial Ownership Limitation. 9.9 - See footnote 2 below. (2) The ownership percentage of Prelude has been calculated on the basis of 43,765,011 shares of voting Common Stock outstanding as of October 28, 2025, as represented to Incyte by Prelude in the Securities Purchase Agreement between Incyte and Prelude, dated as of November 3, 2025, pursuant to which Incyte acquired the shares of Common Stock listed in response to (a) of this Item 4. 4,372,124 0 4,372,124 0 Y Y Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. INCYTE CORP /s/ Sheila A. Denton 11/07/2025